logo
Plus   Neg
Share
Email

BD Reaffirms 2019 Outlook - Quick Facts

While reporting financial results for the third quarter, medical technology company Becton, Dickinson and Co. or BD (BDX) on Tuesday reaffirmed its adjusted earnings and revenue growth guidance for the full-year 2019.

For fiscal 2019, the company continues to project adjusted earnings in a range of $11.65 to $11.75 per share on revenue growth of 8.0 to 9.0 percent or 5.0 to 6.0 percent on a comparable, currency-neutral basis.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $11.68 per share on revenue growth of 8.10 percent to $17.28 billion for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Avalon Furniture is recalling about 9,500 units of Cottage Town Bedroom Furniture collection sold through Rooms To Go due to violation of federal lead paint ban, the U.S. Consumer Product Safety Commission said in a statement. According to the agency, the base coat paint used on pieces within the furniture collection contains levels of lead that exceed the federal lead paint standard. Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of arthritis drug Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints. In the trial, Kevzara was added to best supportive care compared to best supportive care alone (placebo). The companies have stopped the U.S. trial. Shares of Moderna Inc. (MRNA) slipped over 5% on Thursday after a report claimed that the biotechnology company's late-stage trial for a coronavirus vaccine will be delayed. Moderna is developing mRNA-1273 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). The...
Follow RTT